Overall survival in response to sorafenib versus radiotherapy in unresectable hepatocellular carcinoma with major portal vein tumor thrombosis: propensity score analysis

Table 1 Baseline characteristics of 64 patients with Child-Pugh class A and 56 patients matched by propensity score

	Entire cohort			PS-matched cohort
	Sorafenib	RT	Pvalue	Sorafenib	RT	Pvalue
Covariates	n = 36	n = 28		n = 28	n = 28
Age (years)	70 (62–78)	67 (61–71)	0.069	70 (61–78)	67 (61–70)	0.04
Sex (male/female)	31/5	19/9	0.127	23/5	19/9	0.355
HCV	19/17	17/11	0.615	16/12	17/11	1.0
*Main/first branch	7/29	9/19	0.262	7/24	9/19	0.205
Metastases (present/absent)	7/29	2/26	0.278	6/22	2/26	0.252
Previous Treatments (present/absent)	26/10	20/8	1.0	18/10	20/8	0.775
TACE/TAI	21	20		15	20
RFA	3	0		2	0
RT	2	0		1	0
AFP (ng/dL)	1047 (44–5919)	43 (10–1096)	0.005	680 (37–3708)	43 (10–1096)	0.144
DCP (mAU/mL)	2915 (111–19706)	224 (33–2880)	0.013	2151 (58–10775)	224 (33–2880)	0.488

Data are presented as medians (range).
Abbreviations: TACE transarterial chemoembolization, TAI transarterial infusion chemotherapy, RFA radiofrequency ablation, RT radiotherapy, HCV hepatitis C virus, AFP α-fetoprotein, DCP des-γ-carboxy prothrombin, AST aspartate aminotransferase, ALT alanine aminotransferase, PS propensity score.
*Portal tumor invasion to the main trunk or first branch.

ISSN: 1471-230X